Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
about
Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.Targeting the dopamine D3 receptor: an overview of drug design strategies.Automatic Spiral Analysis for Objective Assessment of Motor Symptoms in Parkinson's DiseaseDissociable Effects of Dopamine on the Initial Capture and the Reactive Inhibition of Impulsive Actions in Parkinson's Disease.Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.Clinical pharmacology review of safinamide for the treatment of Parkinson's disease.Carbidopa levodopa enteral suspension.New and emerging medical therapies in Parkinson's disease.Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease.A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.Clinical pharmacology review of opicapone for the treatment of Parkinson's disease.Stimulation of dopamine D2-like receptors in the lumbosacral defaecation centre causes propulsive colorectal contractions in rats.Levodopa: 50 years of a revolutionary drug for Parkinson disease.L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.Heat shock protein 60 affects behavioral improvement in a rat model of Parkinson's disease grafted with human umbilical cord mesenchymal stem cell-derived dopaminergic-like neurons.Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis.Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders.Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease.Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson's disease.Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?A randomized controlled trial of levodopa in patients with Angelman syndrome.Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease
P2860
Q33843079-010F23D6-E8B7-42EC-A95F-CF1A28BF8AD8Q34524556-E2C4774D-D8D8-494B-B5B0-0CF3BA38804AQ36176003-2BAA755E-3B97-48A5-AA8C-10FAB832EDFCQ36977113-E1EC02B9-A2B2-44C9-ABA5-049248C5E950Q37643232-D3E78B6B-0B19-47B0-A387-69FA48BCBDE7Q38640108-602C47FF-D6D3-479B-8FB0-73BBF4728250Q38643494-79866E2B-1F4A-4AED-B1E3-C7BE5BE1C4F7Q38718194-06BF6A92-7980-4AA5-8377-EB092F7304CDQ38748158-DB37AD84-B01A-4933-9F75-98D655DEEBB7Q38811264-B7B357F5-79BF-4538-B353-5265B825C32BQ38811387-FD316604-7791-43B3-A115-E2BC4AA701E4Q38823793-D982A30D-7142-4F8E-9CC7-DDF4D0577133Q38947463-D714395F-6656-45B9-A707-A82DBE88813DQ43346674-6FB5F12B-979A-4ACF-98D0-4D2683FEFC09Q48056860-B91CFD30-D3EB-4D20-B3F3-C1D91F8BB4B2Q48843863-A1DAE876-8488-4749-A011-55848DB9EBF1Q49011363-A386C3EF-DBA7-4C29-8BC1-3D32A1EE545EQ49335971-8D6D6D63-CA24-4765-8528-19ED5FA1B182Q49926091-D6D9F21A-DCE4-432B-B4EA-0E8923A0CD9BQ50105039-6FC43EA3-118D-405E-B43D-511CA5FB17DEQ50203307-4BDD4549-3B90-4E44-8114-39A38C7312E5Q51442945-153A32E8-EE78-46D5-866A-8A365AA81FB0Q52624714-905C712F-0EBC-489F-9E94-835848E338F6Q53532970-CF526C0F-2DEE-4CFE-91F3-F93BC85C5E33Q53642390-4DA6F07F-9DAD-401D-BEEE-FB5F3DB0EC45Q58700802-1F26C8E6-26F4-4C7A-810A-F1C0322EB54B
P2860
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
@en
type
label
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
@en
prefLabel
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
@en
P2860
P356
P1433
P1476
Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
@en
P2093
Peter A LeWitt
P2860
P356
10.1002/MDS.26082
P407
P577
2014-12-01T00:00:00Z